Kalytera Announces Change of Auditor
01 September 2020 - 3:26AM
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the
"
Company" or "
Kalytera")
announced today that Kost Forer Gabbay & Kasierer/Ernst &
Young Global (“E&Y”) have, at the request of the Company,
resigned as auditors of the Company, effective August 20, 2020. The
Company further announced that the Board of Directors has appointed
BDO/BDO Israel (“BDO”) as auditors of the Company effective August
20, 2020.
Commenting on the change, the Company’s
President & CEO, Robert Farrell stated: “The decision to change
auditors was based solely on the Company’s need to complete its
outstanding audit as soon as practicable. Scheduling issues with
E&Y would have caused delays in the resumption and completion
of the audit on their end, and, as a result, E&Y could not
commit to complete the audit prior to October 31. BDO has committed
to complete the audit by the end of September, so, for this reason
the decision was made to engage BDO. Management and the Board of
Directors of the Company thank E&Y for their service and look
forward to completing the audit with BDO.”
The resignation of E&Y and the appointment
of BDO were considered and recommended by the Audit Committee and
approved by both the Board of Directors and the Audit Committee.
There were no reservations or modified opinions in E&Y’s
reports in connection with the financial statements relating to the
relevant period during which E&Y was the Company’s auditor.
There are no “reportable events” (as defined in Section 4.11 of NI
51-102) between the Company and E&Y or with respect of the
change. The Company's Audit Committee and Board of Directors have
reviewed the Notice of Change of Auditors, together with the letter
from E&Y and the letter from BDO, all of which are posted on
the Company’s SEDAR profile accessible at www.sedar.com.
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. ("Kalytera") is
committed to developing new treatments for a variety of diseases
and disorders, by discovering, developing, manufacturing and
delivering innovative human therapeutics. Kalytera focuses on areas
of unmet medical need, and leverages its expertise to find
solutions that will improve health outcomes and dramatically
improve people's lives.
- Website Home: https://kalytera.co/
- News and Insights: https://kalytera.co/news/
- Investors: https://kalytera.co/investors/
Cautionary Statements
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This press release may contain certain
forward-looking information and statements ("forward-looking
information") within the meaning of applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation the timing of the completion of any audit or
related tasks and other statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Readers are cautioned to not place undue reliance on
forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements
depending on, among other things, the risk that future clinical
studies may not proceed as expected or may produce unfavorable
results. Kalytera undertakes no obligation to comment on analyses,
expectations or statements made by third parties, its securities,
or financial or operating results (as applicable). Although
Kalytera believes that the expectations reflected in
forward-looking information in this press release are reasonable,
such forward-looking information has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Kalytera's control. The forward-looking
information contained in this press release is expressly qualified
by this cautionary statement and is made as of the date hereof.
Kalytera disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Contact Information
- Robert FarrellPresident, CEO(888) 861-2008info@kalytera.co
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Apr 2023 to Apr 2024